



Marcel Warntjes resigns from the Board of Directors of SyntheticMR AB (publ)

22 November 2025

SyntheticMR AB (publ) announces today that Marcel Warntjes, at his own request, has decided to resign from his position as a member of the Board of Directors with immediate effect. Marcel Warntjes will remain a member of the Nomination Committee, in his capacity as one of the company's largest shareholders.

"Having founded SyntheticMR almost twenty years ago, I believe the time is now right for me to step down from my role on the Board. The company is entering a very exciting phase in which the continued roll-out of SyMRI 3D, together with the combined technologies of Combinostics and SyntheticMR, has created a strong platform for sustained leadership in the objective quantification of MRI examinations. With CEO Lena Åredal in place, I am confident that the company is well positioned to take the next step, while I look forward to dedicating more time to research," says Marcel Warntjes.

The Board of Directors would like to express its sincere gratitude to Marcel for his extensive and long-standing contributions to the company's development in several key roles over nearly two decades.

For further information, please contact:

Gisli Hennermark, Chairman of the Board, tel. +46 70-420 83 00

Lena Åredal, CEO, tel. +46 76-770 99 08

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-11-2025 15:54 CET.

SyntheticMR AB (publ) develops and markets innovative imaging solutions that enhance neuroimaging workflow efficiency and diagnostic precision. SyntheticMR's SyMRI® solution measures brain absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single fast scan. Combinostics, a SyntheticMR company, offers the AI-powered cNeuro® suite of products that help clinicians make a difference in the lives of patients with neurological disorders. Our products are, among other things, CE-marked and FDA-approved, and we are listed on Spotlight Stock Market Exchange in Stockholm. SyntheticMR is headquartered in Linköping, Sweden, with an additional office in Tampere, Finland. For more information, please visit syntheticmr.com and combinostics.com.